Literature DB >> 23459466

The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia.

T A Lett1, M M Chakravarty, M M Chakavarty, D Felsky, E J Brandl, A K Tiwari, V F Gonçalves, T K Rajji, Z J Daskalakis, H Y Meltzer, J A Lieberman, J P Lerch, B H Mulsant, J L Kennedy, A N Voineskos.   

Abstract

We examined the influence of the genome-wide significant schizophrenia risk variant rs1625579 near the microRNA (miRNA)-137 (MIR137) gene on well-established sources of phenotypic variability in schizophrenia: age-at-onset of psychosis and brain structure. We found that the MIR137 risk genotype strongly predicts an earlier age-at-onset of psychosis across four independently collected samples of patients with schizophrenia (n=510; F1,506=17.7, P=3.1 × 10(-5)). In an imaging-genetics subsample that included additional matched controls (n=213), patients with schizophrenia who had the MIR137 risk genotype had reduced white matter integrity (F3,209=13.6, P=3.88 × 10(-8)) throughout the brain as well as smaller hippocampi and larger lateral ventricles; the brain structure of patients who were carriers of the protective allele was no different from healthy control subjects on these neuroimaging measures. Our findings suggest that MIR137 substantially influences variation in phenotypes that are thought to have an important role in clinical outcome and treatment response. Finally, the possible consequences of genetic risk factors may be distinct in patients with schizophrenia compared with healthy controls.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23459466     DOI: 10.1038/mp.2013.17

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  52 in total

Review 1.  MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.

Authors:  Andrea de Bartolomeis; Felice Iasevoli; Carmine Tomasetti; Elisabetta F Buonaguro
Journal:  Mol Neurobiol       Date:  2014-11-14       Impact factor: 5.590

Review 2.  Heterogeneity and individuality: microRNAs in mental disorders.

Authors:  Leif G Hommers; Katharina Domschke; Jürgen Deckert
Journal:  J Neural Transm (Vienna)       Date:  2014-11-14       Impact factor: 3.575

3.  Processing speed impairment in schizophrenia is mediated by white matter integrity.

Authors:  H Karbasforoushan; B Duffy; J U Blackford; N D Woodward
Journal:  Psychol Med       Date:  2014-05-15       Impact factor: 7.723

4.  MicroRNA-137 regulates a glucocorticoid receptor-dependent signalling network: implications for the etiology of schizophrenia.

Authors:  Astrid Vallès; Gerard J M Martens; Peter De Weerd; Geert Poelmans; Armaz Aschrafi
Journal:  J Psychiatry Neurosci       Date:  2014-09       Impact factor: 6.186

Review 5.  Dysregulation of miRNA and its potential therapeutic application in schizophrenia.

Authors:  Ting Cao; Xue-Chu Zhen
Journal:  CNS Neurosci Ther       Date:  2018-03-12       Impact factor: 5.243

6.  Assessment of Lifespan Functioning Attainment (ALFA) scale: A quantitative interview for self-reported current and functional decline in schizophrenia.

Authors:  Jamie Joseph; William S Kremen; Stephen J Glatt; Carol E Franz; Sharon D Chandler; Xiaohua Liu; Barbara K Johnson; Ming T Tsuang; Elizabeth W Twamley
Journal:  J Psychiatr Res       Date:  2015-04-11       Impact factor: 4.791

7.  Limited Evidence for Association of Genome-Wide Schizophrenia Risk Variants on Cortical Neuroimaging Phenotypes.

Authors:  Aristotle N Voineskos; Daniel Felsky; Anne L Wheeler; David J Rotenberg; Melissa Levesque; Sejal Patel; Philip R Szeszko; James L Kennedy; Todd Lencz; Anil K Malhotra
Journal:  Schizophr Bull       Date:  2015-12-27       Impact factor: 9.306

8.  Brain white matter development is associated with a human-specific haplotype increasing the synthesis of long chain fatty acids.

Authors:  Bart D Peters; Aristotle N Voineskos; Philip R Szeszko; Tristram A Lett; Pamela DeRosse; Saurav Guha; Katherine H Karlsgodt; Toshikazu Ikuta; Daniel Felsky; Majnu John; David J Rotenberg; James L Kennedy; Todd Lencz; Anil K Malhotra
Journal:  J Neurosci       Date:  2014-04-30       Impact factor: 6.167

Review 9.  A comprehensive review of the genetic and biological evidence supports a role for MicroRNA-137 in the etiology of schizophrenia.

Authors:  Kensuke Sakamoto; James J Crowley
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-06-14       Impact factor: 3.568

Review 10.  The epigenome and postnatal environmental influences in psychotic disorders.

Authors:  Ehsan Pishva; Gunter Kenis; Daniel van den Hove; Klaus-Peter Lesch; Marco P M Boks; Jim van Os; Bart P F Rutten
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-02-19       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.